Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2V617F and ASXL1 mutations

In conclusion, we provide preclinical evidence showing that the combination of ruxolitinib and ABT-737 is a promising therapeutic strategy for MPN patients with concurrentJAK2V617F andASXL1 mutations.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research